Lower Estrogen Levels Are A Risk Factor For Knee Osteoarthritis
Main Category: Arthritis / RheumatologyAlso Included In: Endocrinology; Women's Health / Gynecology
Article Date: 28 Jul 2006 - 14:00 PDT
| Patient / Public: | ![]() |
3.88 (8 votes) |
| Healthcare Prof: | ![]() |
3.71 (7 votes) |
Osteoarthritis, which usually develops between the ages of 40 and 50, is more prevalent in women. It is thought that sex hormones may play a role in developing the disease, since they can be involved in inflammation of the tissues affected by it. A study published in the August 2006 issue of Arthritis & Rheumatism (http://www.interscience.wiley.com/journal/arthritis) examined estradiol, the primary estrogen in premenopausal and early perimenopausal women, along with two of the hormones into which it breaks down, to determine if their levels are associated with an increased risk of developing osteoarthritis (OA) in women.
Led by MaryFran R. Sowers of the University of Michigan in Ann Arbor, MI, the study included 842 premenopausal or perimenopausal women from the Southeast Michigan Arthritis Cohort. The women had annual X-rays of both knees along with analysis of blood levels of estradiol and urine levels of 2-hydroxyestrone and 16á-hydroxyestrone, two estrogen metabolites. Patients were also interviewed regarding pain, health, and lifestyle and were followed for three years. The results showed that the women who developed knee OA during the study period had greater odds of having estradiol concentrations and urinary 2-hydroxyestrone levels in the lowest third of the study population, and a higher ratio of 2-hydroxyestrone to 16á-hydroxyestrone, even after adjusting for other risk factors.
"Selected work with animal models provides support for the increased odds of developing OA with lower estradiol concentrations," the authors note. This is one of the few studies that has actually examined hormone concentrations, particularly in relation to new cases of OA, and the first to examine levels of estrogen metabolites. The authors hypothesize that the role of higher 2-hydroxyestrone concentrations in delaying the development of knee OA may be partially through the metabolism of arachidonic acid, a compound from which cells involved in inflammation (such as leukotrienes) are produced, since estrogen metabolites have been shown to play an important role in this pathway.
Previous studies have shown that altered patterns of estrogen metabolism are present in rheumatoid arthritis and systemic lupus erythematosus, suggesting an association with symptoms, such as pain and inflammation, as opposed to disease onset and progression due to structural changes. The authors note that although the 2-hydroxyestrone levels in those with knee OA were significantly lower than in those without the disease, "more detailed investigation is required to establish if primary pathways are associated with symptoms, duration of symptoms, symptom severity, or with response in cartilage and bone."
Given the strong associations of lower estradiol and 2-hydroxyestrone levels with more knee OA, the authors conclude: "If findings are confirmed, then this helps motivate new areas of investigation for intervention. If the mechanistic explanation of 2-hydroxyestrone levels lies, at least in part, in arachidonic acid metabolism associated with pain and inflammation rather than receptor binding, then considering alternative lifestyle and therapeutic pathways to influence these metabolites becomes increasingly viable."
###
Article: "Estradiol and Its Metabolites and Their Association With Knee Osteoarthritis," MaryFran R. Sowers, Daniel McConnell, Mary Jannausch, Ayse G. Buyuktur, Marc Hochberg, David A. Jamadar, Arthritis & Rheumatism, August 2006; (DOI: 10.1002/art.22005).
Contact: Amy Molnar
John Wiley & Sons, Inc.
Visit our arthritis / rheumatology section for the latest news on this subject.
MLA
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/48180.php>
APA
http://www.medicalnewstoday.com/releases/48180.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




